source
- PTC Therapeutics acquires Sangamo’s Fabry gene therapy program for $111 million upfrontPTC Therapeutics announced it has purchased the Fabry disease gene-therapy program (ST-920) from Sangamo Therapeutics. The deal provides $111 million in upfront cash and includes up to $100 millio…
- July biopharma layoffs down 94% YoY, 466 jobs cut across six companiesJuly saw a sharp decline in biopharma workforce reductions, with only 466 employees affected, a 94% drop compared with the same month last year. BioSpace data shows six companies announced or proj…